MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
12.85
-0.82
-6.00%
After Hours: 12.48 -0.37 -2.86% 18:33 03/27 EDT
OPEN
13.57
PREV CLOSE
13.67
HIGH
13.78
LOW
12.79
VOLUME
607.68K
TURNOVER
--
52 WEEK HIGH
16.74
52 WEEK LOW
5.68
MARKET CAP
777.76M
P/E (TTM)
-3.4510
1D
5D
1M
3M
1Y
5Y
1D
Commit To Purchase Cullinan Therapeutics At $9, Earn 25.1% Annualized Using Options
NASDAQ · 1d ago
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
TipRanks · 4d ago
Weekly Report: what happened at CGEM last week (0316-0320)?
Weekly Report · 5d ago
Morgan Stanley Sticks to Their Buy Rating for Cullinan Management (CGEM)
TipRanks · 03/16 12:37
Weekly Report: what happened at CGEM last week (0309-0313)?
Weekly Report · 03/16 09:54
Stifel Nicolaus Sticks to Their Buy Rating for Cullinan Management (CGEM)
TipRanks · 03/13 02:25
Cullinan Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 03/11 13:03
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $36
Benzinga · 03/11 12:53
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.